December 2022
Volume 22, Issue 14
Open Access
Vision Sciences Society Annual Meeting Abstract  |   December 2022
Structural and Functional Changes Among Diabetic Retinopathy Presenting with Macular Edema Following Pre and Post Anti-VEGF
Author Affiliations & Notes
  • Suchismita Rout
    School of Medical science, University of Hyderabad
  • Deepom Sarah
    School of Medical science, University of Hyderabad
  • Deepa M J
  • M ShivaRam
    School of Medical science, University of Hyderabad
  • Footnotes
    Acknowledgements  I would like to convey my gratitude to my supervisor Deepom Sarah John, Deepa MJ, and Shivaram Reddy for their guidance and support. No conflict of interest were reported in this study
Journal of Vision December 2022, Vol.22, 4499. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Suchismita Rout, Deepom Sarah, Deepa M J, M ShivaRam; Structural and Functional Changes Among Diabetic Retinopathy Presenting with Macular Edema Following Pre and Post Anti-VEGF. Journal of Vision 2022;22(14):4499.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Background: In this study we observe the effect of anti-VEGF on structural changes in diabetic macular edema (DME). To assess the changes in contrast sensitivity and visual acuity before and after treatment with anti-VEGF in DME. Methods: This study was conducted at Aravind eye hospital, Mehdipatnam, Hyderabad in a period of 6 months. This study was approved by Institutional Ethics Committee (IEC), University of Hyderabad. Thirty subjects with DME(diabetic macular edema) participated in this study. Informed consent was obtained from all subjects. All the subjects underwent a thorough comprehensive examination which included detailed medical and ocular history, best corrected visual acuity, contrast sensitivity and optical coherence tomography. Visual acuity, contrast sensitivity , central foveal thickness were compared to baseline values between Ranibizumab and Bevacizumab. Results: A total of 48 eyes from 60 eyes met inclusion criteria. Mean age of the subjects was 61 ± 10.97 years. The mean duration of diabetes was 120 ± 66.33 months. Mean visual acuity measurement improved from 0.74logMAR at baseline to 0.36 log MAR (p=0.198) one week after injection further improved to 0.19 log MAR after two weeks. At two weeks, N=23(46%) of Bevacizumab subjects and N=27(54%) of Ranibizumab subjects contrast sensitivity acheived LogMAR 1.0 from its baseline LogMAR 0.30(p=.860) not statistically significant. Mean ± standard deviation baseline central foveal thickness (422±125) microns reduced to (339±109) microns after one week and two weeks (279±77,P=0.182) after treatment. Foveal thickness , visual acuity and contrast sensitivity were not significantly different at each time interval between the groups. Conclusion: Bevacizumab and Ranibizumab appears to have interchangeable effect of improving visual acuity, contrast sensitivity and reducing foveal thickness in the short-term period of treatment. Results of the study concluded that effect of Anti VEGF equally essential as well as effective in improvement in structural and functional changes . Further studies require to obtained positive results regarding improvement in contrast sensitivity .


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.